Single-base precision design of CRISPR-Cas13b enables systematic silencing of oncogenic fusionsWenxin Hu(The University of Melbourne), Mohamed Fareh(Peter MacCallum Cancer Centre)Research SquareJune 28, 202210.21203/rs.3.rs-1714034/v1Cited by 1SaveCiteExport RISWatch citationsRelated PapersTargeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition|Molecular Cell|2021|167Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance|Nature Communications|2021|71